See the DrugPatentWatch profile for trastuzumab

Trastuzumab Emtansine Patents: A Comprehensive Overview

Introduction

Trastuzumab emtansine, also known as T-DM1, is a targeted cancer therapy developed by Genentech, a subsidiary of Roche. It is a combination of trastuzumab, a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2), and emtansine, a microtubule inhibitor. T-DM1 has been approved by regulatory authorities worldwide for the treatment of HER2-positive breast cancer. In this article, we will delve into the patents related to trastuzumab emtansine, exploring the patent landscape and providing insights into the intellectual property strategies employed by Genentech and other stakeholders.

Patent Landscape

Trastuzumab emtansine was first patented in 2006 by Genentech, with the patent application filed in 2004 (US Patent 7,153,819). The patent claims cover the composition of matter, methods of use, and methods of preparation of T-DM1. The patent has since been extended several times, with the most recent extension granted in 2020 (US Patent 10,744,344).

Patent Expirations

The patent for trastuzumab emtansine is set to expire in 2027, with the patent term extending until 2032 due to patent extensions and adjustments. However, it's worth noting that the patent landscape for T-DM1 is complex, with multiple patents and patent applications filed by Genentech and other stakeholders. This complexity may lead to a prolonged patent term, potentially extending beyond 2032.

Patent Challenges

In 2014, a patent challenge was filed by Amgen, a biotechnology company, against Genentech's patent for trastuzumab emtansine (US Patent 7,153,819). Amgen argued that the patent was invalid due to prior art and lack of novelty. However, the patent challenge was ultimately unsuccessful, with the patent being upheld by the US Patent and Trademark Office (USPTO) in 2016.

Patent Portfolio

Genentech has a comprehensive patent portfolio for trastuzumab emtansine, with multiple patents and patent applications filed in various jurisdictions. The patent portfolio covers various aspects of T-DM1, including its composition of matter, methods of use, and methods of preparation. The patent portfolio is designed to provide broad protection for T-DM1, making it difficult for competitors to develop similar products.

Patent Litigation

Patent litigation has been a significant issue for Genentech and other stakeholders in the trastuzumab emtansine market. In 2019, a patent infringement lawsuit was filed by Genentech against Pfizer, a pharmaceutical company, alleging that Pfizer's HER2-targeted cancer therapy, pertuzumab, infringed on Genentech's patents for trastuzumab emtansine. The lawsuit is ongoing, with the outcome uncertain.

Conclusion

Trastuzumab emtansine patents are a complex and dynamic landscape, with multiple patents and patent applications filed by Genentech and other stakeholders. The patent landscape is characterized by patent challenges, patent litigation, and patent extensions, which may prolong the patent term beyond 2032. As the patent landscape continues to evolve, it is essential for stakeholders to monitor patent developments and adjust their intellectual property strategies accordingly.

FAQs

1. What is trastuzumab emtansine?
Trastuzumab emtansine is a targeted cancer therapy developed by Genentech, a subsidiary of Roche. It is a combination of trastuzumab, a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2), and emtansine, a microtubule inhibitor.

2. What is the patent landscape for trastuzumab emtansine?
The patent landscape for trastuzumab emtansine is complex, with multiple patents and patent applications filed by Genentech and other stakeholders. The patent landscape is characterized by patent challenges, patent litigation, and patent extensions, which may prolong the patent term beyond 2032.

3. When does the patent for trastuzumab emtansine expire?
The patent for trastuzumab emtansine is set to expire in 2027, with the patent term extending until 2032 due to patent extensions and adjustments.

4. What is the significance of the patent challenge filed by Amgen?
The patent challenge filed by Amgen against Genentech's patent for trastuzumab emtansine was unsuccessful, with the patent being upheld by the USPTO in 2016. The challenge highlighted the complexity of the patent landscape for T-DM1 and the importance of intellectual property protection for stakeholders.

5. What is the current status of patent litigation related to trastuzumab emtansine?
A patent infringement lawsuit is ongoing between Genentech and Pfizer, alleging that Pfizer's HER2-targeted cancer therapy, pertuzumab, infringes on Genentech's patents for trastuzumab emtansine.

Cited Sources:

1. US Patent 7,153,819 - Genentech, Inc. (2006)
2. US Patent 10,744,344 - Genentech, Inc. (2020)
3. DrugPatentWatch.com - Trastuzumab Emtansine Patent Expiration (2020)
4. Amgen v. Genentech, Inc. - USPTO (2016)
5. Genentech, Inc. v. Pfizer, Inc. - US District Court (2019)

Note: The article is based on publicly available information and is intended to provide a general overview of the patent landscape for trastuzumab emtansine. The information provided is not intended to be legal or financial advice.